These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22439899)

  • 1. Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature.
    Pinto E; Pinelo S; Osório M; Ferreira C; Serra H; Pires I; Barbosa A; Figueiredo H; Felgueira E; Tavares A
    Gynecol Endocrinol; 2012 Jul; 28(7):545-8. PubMed ID: 22439899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone.
    Weissman A; Barash A; Shapiro H; Casper RF
    Hum Reprod; 1998 Dec; 13(12):3421-4. PubMed ID: 9886527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of controlled ovarian hyperstimulation delayed, which occurs after functionally pituitary downregulation by depot GnRH agonist, on the outcome of in vitro fertilization and embryo transfer].
    Ma QH; Li SW; Huang ZY; Han ZY; Qiu DS; Han DW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):980-3. PubMed ID: 18095601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
    Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gonadotropin-releasing hormone antagonist protocol--the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation.
    Kol S; Homburg R; Alsbjerg B; Humaidan P
    Acta Obstet Gynecol Scand; 2012 Jun; 91(6):643-7. PubMed ID: 22428986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal of GnRH agonist decreases oestradiol and VEGF concentrations in high responders.
    Ding LJ; Wang B; Shen XY; Yan GJ; Zhang NY; Hu YL; Sun HX
    Reprod Biomed Online; 2013 Aug; 27(2):131-9. PubMed ID: 23764202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy.
    Christopoulos G; Vlismas A; Barsoum-Derias E; El-Shawarby S; Trew G; Lavery S
    Hum Fertil (Camb); 2015; 18(4):248-52. PubMed ID: 26400626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
    Majumder K; Gelbaya TA; Laing I; Nardo LG
    Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization.
    Fridén BE; Nilsson L
    Acta Obstet Gynecol Scand; 2005 Aug; 84(8):812-6. PubMed ID: 16026411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
    Albuquerque LE; Saconato H; Maciel MC
    Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.
    Huber M; Hadziosmanovic N; Berglund L; Holte J
    Fertil Steril; 2013 Nov; 100(5):1270-6. PubMed ID: 23931964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
    Dosouto C; Haahr T; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.